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INTRODUCTION 
Congenital cystic adenomatoid malformation  (CCAM)  is a rare 
developmental abnormality of the lung.They are similar to benign lung 
tumors (1).The underlying feature of a Congenital cystic adenomatoid 
malformation  is an excessive over growth of terminal respiratory 
bronchioles, forming cysts of various sizes (1).This abnormal lung tissue 
is of defective epithelial-mesenchymal architecture(1,57)  
The congenital lesions are detectable on prenatal ultrasound .They 
appear as solid or cystic masses.Mode of presentation of CCAM vary 
widely  in antenatal and neonatal  period. 
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AIM OF THE STUDY 
• To analyze the effectiveness of ante-natal ultrasonogram 
• To study the age of presentation of congenital cystic adenomatoid 
malformation 
• To analyze the various modes of presentation of congenital cystic 
adenomatoid malformation 
• To analyze the pathology of these lesions 
•  Follow up of the cases during the study period 
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REVIEW OF LITERATURE 
Congenital lung abnormalities are uncommon and diverse in their 
presentation. However, all those who care for infants and children must 
have an appreciation for the diagnosis and treatment of these 
abnormalities because the potential consequencies can be life threatening. 
Inorder to understand the pathophysiology of these malformations ,a 
basic understanding of lung development as well as respiratory 
physiology and anatomy is required and these will be discussed in this 
review of literature. 
EMBRYOLOGY OF LUNG DEVELOPMENT 
During the third week of gestation ,the human embryo develops a 
diverticulum of  the ventral foregut ,which forms the primordium of the 
respiratory system.This is mainly endodermal in origin;however 
,cartilaginous and muscular elements will be derived from the splanchnic 
mesoderm that surrounds the primitive foregut.As the respiratory 
diverticulum grows caudad ,it becomes separated from the foregut by the 
lateral esophageal ridges ,which fuse to form a septum at the end of 
fourth gestational week.Thus,the dorsal esophagus and the more ventral 
trachea and lung buds are defined.The larynx,which is formed from the 
fourth and sixth branchial arches ,maintains communication between the 
pharynx and trachea. 
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The lung buds penetrate the coelomic cavity by caudal growth 
,resulting in the formation of pleuroperitoneal canals on either side of the 
foregut.The expanding lung buds eventual come to nearly fill these 
canals,with the small residual spaces becoming the primitive pleural 
cavities. 
Fetal lung development is divided into five stages; embryonic, 
pseudoglandular, canalicular, saccular and alveolar (2).  Embryonic lung 
development begins during the third week of gestation as a derivative of 
the foregut and is marked by the formation of a diverticulum off of the 
caudal end of the laryngotracheal groove (3).  The trachea and the two 
primary lung buds form from this diverticulum by the fourth week of 
gestation.  At 6 weeks, these lung buds have further developed into 
defined lobar structures.  The pseudoglandular phase of lung development 
takes place during the 7th to 16th weeks of gestation and involves lung 
airway differentiation.  It is during this period that all bronchial airways 
develop.  From the 16th to the 24th weeks of gestation, fetal lung 
development enters the canalicular phase of growth.  During this period, 
airspace development occurs, as crude alveolar air sacs begin to take 
shape.  Type 1 pneumocytes ultimately responsible for surfactant 
production begin to appear. 
Gas exchange becomes functionally possible at this 
stage.Continued maturation of the crude alveolar airspaces takes place 
during the saccular phase of development that extends from 24 weeks 
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gestation to term.  During this time period there is continued remodeling 
of the airspace dimensions and a maturation of surfactant synthesis 
capabilities (4).  Mature adult-like alveoli begin to appear shortly after 
birth (5,6).  Extensive alveolar maturation and multiplication then takes 
place from birth until approximately 8 years of age, with a 10-fold 
increase in the number of functioning alveoli (7,8,9).  Investigators have 
proposed that alveolar formation may be completed by 2 years of age 
(10). 
Pulmonary vascular development follows the stages of airway and 
alveolar growth and can be devided into two anatomic units based on 
associated airway structure.  The term acinus describes the functional unit 
of the lung that includes the respiratory bronchioli, alveolar ducts, and 
alveoli- all structures that evolve during or after the canalicular phase of 
lung development.  Vascular development in this region proceeds 
concurrently with alveolar growth and multiplication.  The preacinar 
structures include the trachea,  major pronchi,  and lobarbronchi up to the 
terminal bronchioles.  Preacinar vascular development is completed by 16 
weeks’ gestational age(11,12,13). 
FACTORS GOVERNING LUNG DEVELOPMENT   
It is now recognized that pulmonary development is marked  by a 
series of programmed events regulated by master genes such as the 
homeobox genes, nuclear transcription factors, hormones, and growth 
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factors.  These processes involve genes regulating epithelial and 
endothelial interactions as well as temporal and spatial interactions if 
several hormones and growth factors.  Early development transcription 
factors such as hepatocyte nuclear factor-3β and thyroid transcription 
factor-I regulate pulmonary development from the foregut mesenchyme.  
Additional stimuli of pulmonary development involve the transforming 
growth factor- β pathway, sonic hedgehog pathway, Notch-delta pathway, 
Wingless-Int pathway ,and  cytokine receptor pathways. Subsequent 
signal transduction control of organogenesis includes the apoptotic 
pathways, nuclear receptor pathways, and interleukin pathways.  
Hormones such as the glucocorticoids, thyroid hormone, and retinoic acid 
have been shown to regulate several of the crucial cellular interactions 
required for proper pulmonary organogenesis and 
differentiation(14,15,16,17,18,19). 
HISTORY 
Congenital cystic adenomatoid malformation was first described as 
distinct pathologic entity by Chin and Tang in 1949(20).Before then 
CCAM was grouped under the general diagnosis of congenital cystic lung 
disease ,along with bronchopulmonary sequestration , congenital lobar 
emphysema and bronchogenic cyst. First ultrasonic detection of CCAM 
was done in the year 1975 by Garret WJ et al 
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INCIDENCE 
The true of cystic lesions is unknown because there are no 
population based studies in literature. Recent studies indicate the 
incidence of CCAM  in the range of 1:35000 to 1:10000. CCAM is the 
most common chest mass detected in the fetus and accounts for more than 
25% of congenital lung lesions 
PRENATAL DIAGNOSIS 
Prenatal diagnosis provides insight into the in utero evolution of 
fetal lung lesions such as congenital cystic adenomatoid malformation 
(CCAM) ,broncho pulmonary malformation and congenital lobar 
emphysema. Serial sonographic study of fetuses with lung lesions has 
helped define the natural history of these lesions ,determine the 
pathophysiologic factors that determine the clinical outcome and 
formulate management based on prognosis(21,22,23,24,25,26). In 
prenatal ultrasonogram it is seen as an echogenic lesion.A series of more 
than 175 prenatally diagnosed cases from the children’s hospital of 
Philadelphia and University of California ,SanFransisco found that the 
overall prognosis depends on the size of lung mass and the secondary 
physiologic derangement: a large mass causes mediastinal shift , 
hypoplasia of normal lung tissue ,polyhydromnios , and cardiovascular 
compromise leading to fetal hydrops and death(27). 
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PATHOPHYSIOLOGY OF FETAL LUNG LESIONS  
Huge fetal lung lesions have reproducible pathophysiological  
effects on the developing fetus. Esophageal compression by the thoracic 
mass causes interference with fetal swallowing of amniotic fluid and 
results in polyhydromnios. Polyhydromnios is common maternal 
condition for pre natal ultrasonography .So , a prenatal diagnostic marker 
exists for large fetal lung tumors. Support for this concept comes from the 
absence of fluid in the fetal stomach in some of these cases and the 
alleviation of fetal hydromnios after effective fetal treatment. The 
hydrops is secondary to venacaval obstruction and cardiac compression 
from large tumors causing extreme mediastinal shift. Like  CCAMs ,a 
fetal BPS can also cause fetal hydrops,either from mass effect or  from  
tension hydrothorax that is the result of fluid or lymph secretion from 
BPS(27).CCAM and BPS form important causes of non-immune hydrops 
fetalis.Hydrops is a harbinger of fetal or neonatal demise and manifests as 
fetal ascitis , pleural and pericardial effusions, and skin and scalp 
edema.Although there is some association of both polyhydromnios and 
hydrops with fetal lung lesions, experience indicates that either can occur 
independently of the other. 
PROGRESSION IN FETAL LIFE 
Large fetal lung tumors may regress in size on serial prenatal 
sonography illustrating that improvement can occur during fetal life 
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(28,29,30). In particular many non cystic BPSs dramatically decrease in 
size and may not need treatment after birth. Many CCAMs also decrease 
in size on serial prenatal ultrasonogram. However, fetal lung lesions that 
seem to disappear on prenatal ultrasonogram and are not seen in post-
natal chest radiograph still need evaluation with CT scan ,which will 
frequently detect a lesion(31). 
CCAM VOLUME RATIO:  
Recently, fetal CCAM volume has been determined by the 
sonographic measurement using the formula for a prolate ellipse (length x 
height x width x 0.52 ). A CCAM volume ratio(CVR) is obtained by 
dividing CCAM volume by head circumference to correct for fetal size. 
ACVR greater than 1.6 is predictive of increased risk of hydrops, with 
80% of these fetuses developing hydrops.The CVR may be useful in 
selecting fetuses at risk of hydrops and thus needing close ultrasound 
observation and possible fetal intervention(32). Serial CVR 
measurements have shown that CCAM growth usually reaches a plateau 
by 28weeks of gestation. For fetuses at less than 28 weeks gestation , the 
recommendation is twice weekly ultrasound surveillance if the CVR is 
greater than 1.6 and initially weekly surveillance for fetuses with smaller 
CVR values. 
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CLASSIFICATION 
Major distinctive pathological (and radiological) features allow to 
classify CCAM into following broad categories.Historically  congenital 
cystic adenomatoid malformations have been divided by Stocker into 3 
types. 
1. STOCKER TYPE I :large cyst (>2cm) 
Currently referred to as the macrocystic CCAMs  based on gross 
anatomy and ultrasound findings(34) .These consist of large sometimes 
multiple or multiloculated cysts.They are the result of  terminal 
bronchiolar proliferation with associated suppression of alveolar 
development. They are not true cysts and always communicate with 
proximal airway and distal lung parenchyma(33). Histologically they are 
lined with respiratory ciliated cuboidal or columnar epithelium. 
2. STOCKER TYPE II 
Currently referred to as microcystic CCAM.These consist of small 
uniform multiple or multiloculated cysts.They are not true cysts and are 
lined by ciliated columnar or cuboidal epithelium. 
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3. STOCKER TYPE III:( solid lesion ) 
These are macroscopically and microscopically solid lesions 
without cysts. Pathologically these are grouped into pulmonary 
hyperplasia group. Stocker JT suggested a new name ,congenital 
pulmonary airway malformation in an article in histopathology journal in 
the year 2002(36). 
BLOOD SUPPLY 
CCAM receives its blood supply from the pulmonary circulation 
and is not sequestered from the tracheobronchial tree. However, type II 
and III lesions can occasionally coexist with extralobar 
sequestration(hybrid lesions), and in such cases, they may receive 
systemic arterial supply 
HISTOLOGY 
CCAM is differentiated from other congenital cystic diseases by 4 
characteristics : 
(I) Polypoid projections of the mucosa 
(II) An increase in smooth muscle and elastic tissue in cyst walls 
(III) Absence of bronchial cartilage (unless it is trapped within 
the lesion)  
(IV) Presence of tall columnar mucinous epithelium 
(V) Absence of inflammation (35,58) 
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MANAGEMENT IN ANTENATAL AND POSTNATAL LIFE: 
ANTENATAL DIAGNOSIS 
Cystic lung lesions are the most commonly identified pulmonary 
lesions in prenatal ultrasonography which has proved its diagnostic 
accuracy in 70% of cases(37).On occasion cystic lung lesion in lung base 
may be confused with a diaphragmatic hernia ;or a pulmonary 
sequestration can be confused with CCAM if USG dost not identify 
systemic feeding vessel in Doppler.In these unclear cases ,ultrafast MRI 
can provide more detailed anatomic assessment to make a 
diagnosis(38).Serial prenatal USG is needed in the follow up of these 
prenatally diagnosed lesions. 
POSTNATAL DIAGNOSIS 
If the lesion is not identified prenatally, then a two-view chest 
radiograph is the first diagnostic study in a patient with respiratory 
symptoms; but it can appear normal and, unless a high index of suspicion 
is maintained, the diagnosis can be missed.(39) If an abnormality is 
identified on chest radiography, or if the chest radiograph is normal but 
the patient is symptomatic, then a confirmatory study can be performed 
next. The choice of study is dependent on the patient’s symptoms and 
likely diagnosis. Confirmatory studies include CT scan (hyperinflation is 
better seen, systemic arterial supply to sequestrations seen in 60% of the 
cases), 7 ultrasonography, and contrast esophagography (to demonstrate 
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communication between the respiratory tract and esophagus or stomach 
in sequestration for example (40) Occasionally, magnetic resonance 
imaging and bronchoscopy are necessary (41). Rarely is angiography 
needed to make the diagnosis or aid in preoperative planning particularly 
in cases of severe inflammation. Its potential complications outweigh its 
benefits especially in infants. (42) In such cases, MR angiography may be 
the study of choice. (43,44) 
ROLE OF FETAL INTERVENTION 
The finding that fetuses with hydrops are at very high risk for fetal 
or neonatal demise led to the performance of either fetal surgical 
resection of the massively enlarged pulmonary lobe (fetal lobectomy) for 
cystic /solid lesions or thorcoamniotic shunting for lesions for lesions 
with a dominant cyst(45,46). Lesions with associated hydrops that are 
diagnosed late in gestation may benefit from resection using an Ex-utero 
Intrapartum therapy approach(EXIT)(47) .The fetus with a lung mass but 
without hydrops has an excellent chance for survival with maternal 
transport ,planned delivery ,and neonatal evaluation and surgery.        
A few fetuses may develop fluid collections within the chest cavity 
and in those situations a Harrison catheter shunt can beused to drain the 
fluid into the amniotic fluid. Very large cystic masses might pose a danger 
during birth because of the airway compression. In this situation, a 
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special surgical type of delivery called the EXIT procedure can be 
done(48). 
In rare extreme cases, where fetus's heart is in danger, fetal surgery 
can be performed to remove the CCAM. If non-immune hydrops fetalis 
develop, there is a near universal mortality of the fetus. Fetal surgery can 
improve the survival. 
NEONATAL SURGERY 
Neonates with respiratory compromise due to a cystic lung lesions 
require prompt surgical resection ,usually by lobectomy. In most severe 
cases, ventilatory support with high frequency ventilation or 
extracorporeal membrane oxygenation may be required. 
MANAGEMENT OF ASYMPTOMATIC PATIENTS 
In asymptomatic neonates with a cystic lung lesion ,it is believed 
that elective resection is warranted because of the risks of infection and 
occult malignant transformation(71). 
AGE OF SURGICAL RESECTION 
Postnatally CCAM is confirmed by contrast CT scan .Most experts 
suggest elective  resection of CCAM at one month of age or later. 
 
 
15
MORTALITY/MORBIDITY 
The prognosis primarily depends on the size of the lesion. In a 
Canadian series of 48 patients, the incidence of postnatal demise was 
10% (10 of 40 patients) with 8 spontaneous and voluntary abortions. 
Larger lesions have a higher incidence of mediastinal shift, vascular 
compromise, polyhydramnios, pulmonary hypoplasia, and hydrops, 
which may lead to intrauterine fetal demise or neonatal death.   
The most commonly associated anomalies occur in the type II 
form. The anomalies affect the renal (cystic disease, agenesis dysgenesis), 
intestinal (atresias), cardiac, and osseous systems. 
Type III CCAM tends to be extensive and therefore tends to have a 
poor prognosis. The prognosis is also poor with bilateral lung 
involvement, prematurity, and severe associated malformations.  
MALIGNANCIES ARISING FROM CCAM 
Children with CCAM have increased risk of developing 
malignancy.Malignancy mainly consist of pulmonaryblastoma and 
rhabdomyosarcoma in infants and young children and bronchoalveolar 
carcinoma in older children and adults(49,50,51,52,53). 
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DIFFERENTIAL DIAGNOSIS FOR CCAM 
The differential diagnosis for fetal lung space occupying  lesions 
include 
 A)  Diaphragmatic hernia, 
B)  Pulmonary sequestration, 
C)  Bronchogenic cysts, and  
D)  Congenital lobar emphysema. 
DIAPHRAGMATIC HERNIA 
Congenital diaphragmatic hernia (CDH) is a rare congenital 
anomaly characterized by a defect in diaphragm development with 
subsequent herniation of abdominal contents into the thorax. The two 
most prevalent types are herniation anteriorly in the diaphragm 
(Morgagni hernia) and posterolateral (Bochdalek-type) hernias. The 
incidence of posterolateral CDH has been reported from between 1 in 
2,000 and 1 in 5,000 live births (54). Classically, infants with CDH 
present in respiratory distress either at birth or within the first few hours 
of life. Currently, between 40% and 60% of infants with CDH are 
diagnosed prenatally (55). 
The diagnosis of congenital diaphragmatic hernia is suspected 
when the prenatal ultrasound demonstrates the heart in an abnormal 
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location and fluid-filled loops of bowel are visualized in the thorax. The 
diagnosis can be confused with a cystic adenomatoid malformation of the 
lung, and a fetal magnetic resonance imaging may be helpful to 
distinguish the two (56) In infants who present at or after delivery, 
respiratory distress is the main complaint. The infant will often have a 
scaphoid abdomen. There may be bowel sounds in the chest. Location of 
the nasogastric tube in the thorax on radiograph or an upper 
gastrointestinal contrast study will aid in confirming the 
diagnosis.Treatment for congenital diaphragmatic hernia is 
surgery.Recent trend is to first stabilize the patient ,and surgical repair at 
an appropriate time. 
BRONCHOPULMONARY SEQUESTRATION 
Pulmonary sequestrations make up10-30% of the cystic 
bronchopulmonary foregut malformations. Bronchopulmonary 
sequestrtions (BPS) may be intralobar or extralobar sequestration.In both 
types of BPS there is no communication between the sequestrum and the 
normal tracheo-branchial tree.On prenatal USG ,a BPS appears as a well 
defined echodense,homogenous mass.Detection by color flow Doppler of 
a systemic artery or arteries from the aorta to the fetal lung lesion is 
pathognomonic of BPS(59).However  if this finding is not detected ,an 
echodense CCAM and a BPS can have similar prenatal sonographic 
appearance.Ultrafast fetal magnetic resonance imaging can differentiate 
CCAM and BPS(60). Furthermore there are prenatally detected lung 
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masses that display clinicopathogenic features of both CCAM and BPS 
.These are called as hybrid lesions denoting shared embryonic basis for 
these lung lesions(61,62,63). An intralobar sequestration is most 
commonly seen in the medial basal or posterior basal segments of the 
lower lobes, left side more common than the right side. Usual postnatal 
presentation of  intralobar BPS is recurrent pneumonia and even abscess 
formation with in the BPS. Extralobar BPS is more frequent in males ,is 
more common on the left side. Extralobar BPS is associated with 
conditions such as congenital diaphragmatic hernia,vertebral anomalies 
and congenital heart disease. 
CONGENITAL LOBAR EMPHYSEMA 
Fundamental mechanism of  congenital lobar emphysema(CLE)  is 
that the affected bronchus allows passage of air on inspiration but only 
limited expulsion of air on expiration leading to lobar overexpansion. Air 
trapping in CLE lobe may be due to     ( a) dysplastic bronchial cartilages 
creating a ball valve effect or a complete bronchial atresia; (64,65) (b) 
endobronchial obstruction from inspissated mucus or extensive mucosal 
proliferation and infolding; (66) (3) extrinsic compression of the bronchi 
from aberrant cardiopulmonary vasculature or enlarged cardiac 
chambers;(67) and (4) diffuse bronchial abnormalities that may or may 
not be related to infection(68).The most common site of involvement for 
CLE is the  left upper lobe (40% to 50%), followed by the right middle 
lobe (30% to 40%) and right upper lobe (20%).Congenital lobar 
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emphysema can be distinguished prenatally from other cystic lung lesions 
on ultrasonography by increased echogenicity reflectivity compared with 
a microcystic CCAM and the absence of systemic arterial blood supply 
compared with a BPS(69,70).Progressive enlargement of these lesions 
prior to 28 weeks gestation may be due to fetal lung fluid trapping in the 
lobe analogous to the air trapping seen postnatally. Late in the gestation 
CLE may regress in size and the character of the mass ,rendering it 
indistinguishable from adjacent normal fetal lung. Postnatal assessment is 
important is because of postnatal air trapping in the emphysematous lobe. 
At the time of birth the affected lobe may be radioopaque on chest X-ray 
because of the delayed clearance of fetal lung fluid. CLE is diagnosed at 
birth in about 25% of cases and by the age 1 month in about 50%.The 
diagnosis is sporadic after 6 months of age. If the presentation is 
respiratory distress and pulmonary lobar hyperinflation ,then the main 
stay of management is resection of  emphysematous lobe. 
CONGENITAL BRONCHOGENIC LUNG CYSTS 
Bronchogenic cysts are typically thick walled,unilocular lesions 
which are comprised of smooth muscle ,cartilage and mucous glands 
lined by pseudostratified ciliated columnar epithelium.It is believed that 
they become separated from the tracheobranchial tree during 
development,but remain adjacent ,which is they are found clinically. 
Congenital lung cysts may develop at any time between the third and the 
16th weeks of gestation as the lung buds begintheir initial segmental 
 
20
divisions and subsegmental dichotomous divisions 
progress.Bronchogenic cysts arise from the trachea ,bronchus and other 
conducting airways but have usually lost their connection with their 
parent structure.They are usually simple ,contain mucous however, air  
fluid levels and infection may be seen if there is continuity with 
tracheobronchial tree .Majority of bronchogenic cysts are found in the 
lung parenchyma and mediastinum. If symptomatic most common 
presentations are  wheezing, tachypnoea or dyspnoea ,all related to 
compression of the adjacent conducting airway with partial obstruction.If 
there is patent connection with tracheobronchial tree ,the may get infected 
and the child may present with features of infection. CT or MRI imaging 
will allow  these lesions to be differentiated from other congenital cystic 
lung  lesions.  
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PATIENTS AND METHODS 
It is a combined prospective and retrospective study which 
included patients with congenital cystic adenomatoid malformation, who 
attended the pediatric surgery OPD at the Institute of Child Health and 
Hospital for Children, Madras Medical College, Chennai. The study was 
done during the three years period, from Jan 1, 2007 to Dec 31, 2009. 
Selection Criteria 
Inclusion Criteria 
All patients had proven congenital cystic adenomatoid 
malformation radiologically. 
Exclusion Criteria 
• All cases of bronchopulmonary sequestration 
• All cases of congenital lobar emphysema 
• All mediastinal cystic lesions like bronchogenic cyst, neurenteric 
cyst, cystic teratoma  and pericardial cyst 
The patients were subjected to detailed clinical examination and 
relevant investigations were performed, namely, chest x-ray  and CT scan 
chest . 
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The treatment modalities were studied and patients were followed 
up to assess the effectiveness after 6 months of surgery with relevant 
investigations and extended to the available period. The results were 
tabulated and analyzed 
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OBSERVATIONS 
This study of congenital cystic adenomatoid malformation 
presented to Pediatric Surgery Department , ICH&HC, MMC, Chennai 
was undertaken between January 2007 to December 2009. The following 
facts were obtained: 
During the study period of 3 years from January 2007 to December 
2009, twenty patients fulfilled the criteria. Out of these 20 patients ,five 
patients presented in 2007 ,seven patients presented in 2008 and eight 
patients presented in 2009. 
Number of cases in 2007 5 
Number of cases in 2008 7 
Number of cases in  2009 8 
Total 20 
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ANTENATALLY DETECTED CASES 
Out of these twenty patients, seven were ante-natally diagnosed. 
Among these cases five patients presented in 2009, one each in 2007 and 
2008.This may be due to increase in the efficiency and familiarity of the 
sonologists in dealing with fetal lung lesions.Majority (five) of 
antenatally detected patients were asymptomatic at the time of 
presentation.  
Remaining two patients were admitted with complaints of having   
respiratory distress since birth .One patient was admitted soon after birth 
,and was put on mechanical ventilation.Child was on ventilator for 23 
days and expired.The other one presented on 34th day of life and was 
evaluated and successfully operated. 
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SEX DISTRIBUTION 
In this study, 11 patients were male and the remaining 9 were 
female.There is no sex predilection for patients with CCAM. 
MALE 11
FEMALE 9 
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9
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AGE OF PRESENTATION 
Among our study group of  twenty patients , 7 patients presented in 
the neonatal period ,11 presented between 1 month and 1 year,2 patients 
presented between 1 to 5 years .No patient was seen above 5 years of 
age.This means that  90% of CCAM  patients in our study are below one 
year of age .High degree of suspicion is needed to detect CCAM in 
infants if they are not antenatally diagnosed. 
UPTO 1 MONTH 7 35% 
1 MONTH TO 1 YEAR 11 55% 
1 TO 3 YEARS 1 5% 
3 TO 7 YEARS 1 5% 
7 TO 12 YEARS 0 0% 
 
 
 
 
 
 
37
 
 
AGE WISE DISTRIBUTION OF CCAM PATIENTS 
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EFFECTIVENESS OF ANTENATAL USG 
In the patients who were enrolled for study 18 underwent atleast 
one antenatal USG.2 patients didn’t have any antenatal USG. Among this 
group of 18,only 7 were suspected to have cystic lesion in lung.This 
means that only 39% patients were detected antenatally.  Internationally, 
screening antenatal USG detects about 70% of CCAMs.Of the 18 patients 
who went antenatal USG ,only one patient had polyhydromnios.But this 
infant was not detected to have CCAM antenatally. 
AN USG done patients  18 (90%) 
AN USG not done          02 (10%) 
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AN natal USG detecting CCAM 7 (39%) 
AN USG not detecting CCAM 11 (61%) 
(Two patients didn’t have AN USG) 
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MODE OF PRESENTATION 
 
PRESENTING COMPLAINTS NUMBER OF CASES 
Asymptomatic 5 
Respiratory distress since birth 3 
Fever with cough 6 
Dyspnoea with cough 4 
Cough with wheeze 2 
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CCAM presents in various forms. In our study, 5 asymptomatic 
patients attended surgical OPD.All these five were antenatally detected.  
Three patients presented with complaints of respiratory distress 
since birth.Among these three ,two patients presented on the 1st day of 
life.One patient with respiratory distress since birth presented on 34th day 
of life.  
Six of our patients presented with fever and cough .Among this 
group, three were initially treated outside  as bronchopneumonia ,Two 
patients as empyema and one as loculated pyopneumothorax. Four 
CCAM patients presented with difficulty in breathing and two presented 
with wheeze. 
Patients with empyema and loculated pyopneumothorax were 
initially treated with intercostal chest tube drainage .Only later they were 
found to have CCAM. 
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SENSITIVITY OF CHEST X-RAY 
X-RAY diagnosis  
CCAM                                    10 
Bronchopneumonia                5 
Lung cyst                                2 
Empyema                                2 
Pyopneumothorax                   1 
 
All of our patients had chest radiography at the time of admission. 
Radiologists were able to suggest the diagnosis of CCAM in only 10 
patients. For two patients they gave the diagnosis of lung cyst and for five 
patients they gave the diagnosis of bronchopneumonia. Two patients were 
diagnosed to have empyema and one was diagnosed to have loculated 
pyopneumothorax. 
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ROLE OF CT SCAN CHEST 
CT scan was done in 18 of our CCAM patients. Among these 
children 16 were diagnosed to have CCAM ,one was found to have ?BPS 
and one was diagnosed as loculated pyopneumothorax.This shows 
postnatal CT scan has a higher diagnostic value for detecting lung lesions. 
CT scan picking up CCAM 16 
?BPS 1 
Loculated pyopneumothrax 1 
 
CT SCAN  FINDINGS IN CCAM
16
1 1
CT scan picking up CCAM ?BPS Loculated pyopneumothrax
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LATERALITY OF LESIONS  
   Right side lesions 9    (45%) 
Left side lesions 10    (50%) 
Bilateral lesions 1     (5%) 
 
In our study group 9 patients had right sided lesions ,10 patients 
had left sided lesions and 1 had bilateral congenital cystic adenomatoid 
malformation.  
LATERALITY OF LESIONS
9
10
1
   Right side lesions Left side lesions Bilateral lesions
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LOBE INVOLVED 
Upper lobe 2   (11%) 
Upper & middle lobe 3  (17%) 
Middle lobe 2   (11%) 
Lower lobe 11   (61%) 
 
LOBAR INVOLVEMENT
2
3
2
11
Upper lobe Upper & middle lobe Middle lobe Lower lobe
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Lower lobe is the most affected lobe .Lower lobe was affected in 
11 patients, upper lobe 2 patients, middle lobe 2 patients and 3 patients 
had both upper and middle lobe involvement. An article in seminars in 
paediatric surgery( 2008 ) 17 ,2-8 ;by Christina M.Shanthi also endorses 
the fact that lower lobe is most commonly affected lobe and there is no 
left to right side difference in the presentation of CCAM. 
Lower lobectomy was done in 10 patients(right-3;left-7) , upper 
lobectomy was done in 5 patients(right -4 ,left 1) and middle lobectomy 
was done in 5 patients. Among the above patients combined upper and 
middle lobectomy was done in 3 patients.One patient who presented with 
empyema also underwent decortication. 
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POST OPERATIVE PERIOD 
Postoperative period was uneventful in 8 patients. 4 patients had 
wound infection, 2 patients needed post operative ventilatory support. 
Antenatal detected patients were operated after one month of age. 
Uneventful 11 patients 
Wound Infection  4 patients 
Post operative Ventilatory support 2 patients 
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DURATION OF HOSPITAL STAY 
Average duration of hospital stay for operated patients was 14.4 
days.But the average hospital stay duration of antenatal detected patients 
was significantly less .It is about 10 days for antenatal detected 
patients.So it is clear that infected CCAM patients had longer hospital 
stay. 
ASSOCIATED ANOMALIES 
In our study 2 patients had congenital heart disease and one patient 
had glycogen storage disease type III. In our study there was no 
association with bronchopulmonary sequestration. 
Congenital Heart Disease 2 
Glycogen Storage Disease Type III 1 
Bronchopulmonary sequestration 0 
 
ASSOCIATED ANOMALIES
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PATHOLOGY REPORT OF LESIONS 
Stocker type I 16 cases (94%) 
Stocker type III 1 case  (6%) 
 
In our series 94% of cases belong to Stocker type I lesion and 6% 
of cases belong to Stocker type III lesion. 
FOLLOW UP 
In our series there is no mortality among operated patients Among 
the 17 patients who we have operated, 15 patients turned up for follow 
up. Out of this, two patients were  treated for respiratory tract infection. 
Their chest X-ray are normal. Pulmonary function tests are planned for 
the future. 
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CONCLUSION 
• Most of CCAM patients present early in life (< 1 year) 
• In our setup the ability of antenatal USG to detect lung lesions is 
only 39% 
• Antenatally detected patients , report to the hospital earlier than the 
other patients. 
• Presenting symptoms vary widely from mild respiratory tract 
infection to empyema. 
• CT scan chest is the investigation of choice. 
• Antenatally detected patients are usually asymptomatic 
• Patients with pulmonary infection have a longer hospital stay and 
have higher incidence of postoperative complications. 
• Majority of our patients (94%) belonged to Stocker type I group. 
• Our patients are free of respiratory problems in their followup. 
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Name IP No Sex
age of 
presentation
AN 
USG
AN CCAM 
Diag Presenting Complaints CXR Diagnosis CT Scan
Lobe 
Affected Side Treatment Post OP period
Hospital 
Stay
ammu 616878 F 6 months done not done bronchopneumonia Rt lung cyst CCAM lower lobe right Rt L.Lobectomy uneventful 12 days
b/o lakshmi 670204 M 14 days done not done dyspnoea-4days;wheeze s/o CCAM CCAM lower lobe left Lt.L.lobectomy
pp
change 
on V POD 22 days
b/o malathi 667307 M 45 days done done asymptomatic ?CCAM ?BPS CCAM ?BPS lower lobe left Lt.L.lobectomy uneventful 8 days
b/o mumtaz 670909 F 45 days done done asymptomatic ?CCAM CCAM lower lobe right Rt L.Lobectomy uneventful 8 days
ebenezer 657668 M 5 months done not done dyspnoea-4d,fever-2d Rt lung cyst CCAM middle lobe right Rt M.Lobectomy uneventful 21 days
pavithra 641640 F 4 1/2 years done not done recurrent RTI;fever-2 wk Lt pleural effusion CCAM lower lobe left Lt.L.lobectomy wound infection 12 days
savitha 646679 F 11 months done not done recurrent RTI; bronchopneumonia CCAM upper lobe left Lt.U.lobectomy uneventful 10 days
srinivasan 607752 M 15 months not done not done fever-20d;cough&wheeze-3d bronchopneumonia CCAM lower lobe left Lt.L.lobectomy ICD change on III POD 11 days
surya 602012 M 3 months done not done cough-2M;dyspnoea-1 M bronchopneumonia CCAM U&M lobes right Rt.U&M.lobectomy
seizures on II POD -
dyselectrolytemia 20 days
rasaiya 604871 M 11 months done not done fever-15d;cough-15d Rt empyema ?CCAM lower lobe right Rt.L.Lobectomy;decortication wound infection 28 days
raja 595229 M 4 months done not done fever-10d;dyspnoea-7d Lt pyopneumothrax
loculated 
pyopneumothorax lower lobe left Lt.L.Lobectomy wound infection 18 days
nethra 592451 F 34 days done done Resp.distress since birth CCAM CCAM U&M lobes right Rt.U&M.lobectomy iCD change on IV POD 15 days
b/o vanitha 586883 F 8 days done done asymptomatic CCAM left unwilling for surgery
b/o porkodi 577108 F 28 days done done asymptomatic B/L CCAM CCAM lower lobe right&left unwilling for surgery
rahul 540563 M 28 days done not done Resp.distress since 5th day bronchopneumonia CCAM lower lobe left Lt.L.lobectomy with lingula vent.support-2d 10 days
b/o sathyavathi 527560 M 1st day done done asymptomatic CCAM CCAM middle lobe right Rt.M.lobectomy uneventful 9 days
anantheeswar 586730 M 7 months done not done resp.distress -1 month CCAM CCAM U&M lobes right Rt.U&M.lobectomy uneventful 13 days
swedha 532438 F 8 months not done not done fever&cough-15 days bronchopneumonia CCAM upper lobe right Rt.U.lobectomy wound infection 17 days
b/o harini 658003 M 1 st day done done Resp.distress since birth CCAM not done left Mech.ventilation for 23 days
b/o manjula 653115 F 1 st day done not done Resp.distress since birth CCAM CCAM lower lobe left Lt.L.lobectomy in 2nd month uneventful 10 days
MASTER CHART 
Asso Findings
GSD type III
unwilling for surgery
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PROFORMA 
Personal Details -  
Name    Age    Sex 
IP No. 
Address  
Date 
Ante-natal Scan –  
□ Done  
Report -  
□ Not Done -  
Clinical Symptoms 
□ Asymptomatic     □ respiratory distress   
□ recurrent LRI      □ failure to thrive  
□ Empyema     □ Others 
□ Others  
Laterality  
□ U/L (Rt/Lt)  
□ B/L-  
 24
Investigations 
BU/SC/SE – 
CBC   
Blood grouping and typing 
Chest X-ray 
USG Chest 
CT chest 
Treatment 
□ Surgery -  
Surgical Details 
Age at surgery 
Type 
Approach 
HPE Report 
*Polypoid projections of the mucosa 
*An increase in smooth muscle and elastic tissue in cyst wall 
*An absence of cartilage 
*Presence of mucus secreting cells 
*To note the presence of hybrid lesions 
Post-op Evaluation 
Clinical Symptoms 
□ Asymptomatic     □ Failure to thrive   
□ Recurrent respiratory tract infections    
□ Others 
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CONGENITAL CYSTIC ADENOMATOID MALFORMATION 
PER OPERATIVE PHOTOGRAPH: 
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H &E STAINING OF CCAM: 
MICRO CYSTIC TYPE OF CCAM 
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MACRO CYSTIC TYPE OF CCAM
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H & E STAIN SHOWING ABUNDANCE OF ELASTIN AND 
ABSENCE OF CARTILATE
 29
ANTENATAL ULTRASONOGRAPHY OF CCAM: 
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CHEST RADIOGRAPH OF CCAM PATIENT: 
 
CT SCAN PICTURE OF CCAM PATIENT: 
 
 
 31
CCAM PRESENTING AS EMPYEMA: 
 
 
 Barium study in CCAM misdiagnosed as CDH in X-ray chest ; 
 
